- Home
- NXP vs ORIC Comparison
NXP vs ORIC Comparison
Compare NXP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXP | ORIC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 861.3M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NXP | ORIC |
|---|---|---|
| Price | $14.23 | $13.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 142.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $7.23 |
| 52 Week High | $14.65 | $14.93 |
Technical Indicators
Market Signals| Indicator | NXP | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 58.75 |
| Support Level | $14.23 | $13.12 |
| Resistance Level | $14.49 | $13.97 |
| Average True Range (ATR) | 0.09 | 0.63 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 48.02 | 52.96 |
Price Performance
Historical ComparisonAbout NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.